Three or four mainland Chinese CROs are listed on the Nasdaq. "In addition to TG-0054, TaiGen is also developing enrofloxacin, a potent antibiotic that is effective against Staphylococcus aureus. The drug has just completed phase II clinical trials at multiple organizations in a number of different countries for its second indication-diabetic foot-and will soon be submitted to the US FDA for approval.
除了 TG-0054，太景手上還有可以殺死黃金葡萄球菌的超級抗生素「奈諾沙星」，8 月才剛做完第二個適應症糖尿病足感染的多國多中心第二期臨床試驗，正準備把結果送到美國食品藥物管理局審查。